Acknowledgements
The authors would like to thank all patients and their families and caregivers, the Cabozantinib-2001 investigators and their team members at each study site and colleagues from Takeda Pharmaceutical Company Limited. Graphical assistance was provided by MIMS Japan Co., Ltd., Tokyo, Japan, and editorial support was provided by Steven Inglis, PhD, and Angelica Papanicolaou, PhD, of Oxford PharmaGenesis, Melbourne, Australia, which was funded by Takeda Pharmaceutical Company Limited, Tokyo, Japan, in accordance with Good Publication Practice 3 (GPP3). Kazumi Nomura, PhD (Takeda Pharmaceutical Company Limited) is acknowledged for medical writing assistance.